Keagan Lenihan Joins Philip Morris International as Vice President, Head of D.C. Office
03 Mai 2022 - 3:00PM
Business Wire
Philip Morris International Inc. (PMI) (NYSE: PM) announced
today that it has appointed Keagan Lenihan as Vice President of
Government Affairs and Public Policy, and Head of its D.C. office.
Lenihan will serve as the Washington, D.C. lead for PMI’s
U.S.-based external affairs efforts as the company continues to
advance on its journey away from cigarettes, reporting to members
of the company’s senior management team in the U.S. and
globally.
Lenihan joins PMI from Altoida, Inc., a medical device company
that uses AI and AR to predict neurological disease, where she
served as Vice President of Operations. Over the previous two
decades, she worked in government and corporate and public policy,
most recently as Associate Commissioner for External Affairs and
Strategic Initiatives and then Chief of Staff of the U.S. Food and
Drug Administration (FDA). In these positions, she oversaw daily
management of the agency and provided strategic direction to senior
leadership on policy priorities, including efforts to promote
medical product innovation, tackle opioid abuse, identify solutions
to prescription drug shortages, and pursue a comprehensive plan for
tobacco regulation, with an emphasis on preventing youth use of
tobacco products.
“We are thrilled that Keagan will be joining us to further
accelerate PMI’s journey toward a smoke-free future,” said Deepak
Mishra, President of PMI Americas. “Her passion for and expertise
in healthcare, life sciences, and policy issues and her commitment
to help our company reach the next phase in its ambitious
transformation away from cigarettes make her an ideal addition to
our global leadership team.”
Prior to the FDA, Lenihan was Senior Counselor to the Secretary
of Health and Human Services, overseeing an extensive portfolio of
policy initiatives and reforms, including comprehensive drug
pricing reform, price transparency, and regulatory reform. Before
that, she was Special Assistant to the President, charged with
managing hiring for the Department of Health and Human Services,
Department of Education, Department of Housing and Urban
Development, Department of Labor, and Office of Personnel and
Management.
Earlier, Lenihan was Senior Director of Government Relations for
McKesson Specialty Health. She also worked for almost a decade on
Capitol Hill, serving three members of Congress who held positions
in House leadership, as well as senior members of the Ways and
Means and House Rules committees.
Keagan Lenihan commented: “Having spent two decades working to
improve public health, I am delighted to join forces with PMI in
their mission to move away from cigarettes and help current smokers
who otherwise would not quit switch to less harmful alternatives
while ensuring we protect youth. PMI is not just transforming its
business; with its smoke-free commitment, it is revolutionizing its
industry and championing an unprecedented breakthrough for public
health, including moving beyond nicotine to meet patient and
consumer needs in the wellness and life sciences spaces. I’m
excited to have been invited to play a role in making this happen
even faster.”
Philip Morris International: Delivering a Smoke-Free
Future
Philip Morris International (PMI) is a leading international
tobacco company working to deliver a smoke-free future and evolving
its portfolio for the long-term to include products outside of the
tobacco and nicotine sector. The company’s current product
portfolio primarily consists of cigarettes and smoke-free products,
including heat-not-burn, vapor and oral nicotine products, which
are sold in markets outside the U.S. Since 2008, PMI has invested
more than USD 9 billion to develop, scientifically substantiate and
commercialize innovative smoke-free products for adults who would
otherwise continue to smoke, with the goal of completely ending the
sale of cigarettes. This includes the building of world-class
scientific assessment capabilities, notably in the areas of
pre-clinical systems toxicology, clinical and behavioral research,
as well as post-market studies. The U.S. Food and Drug
Administration (FDA) has authorized the marketing of versions of
PMI’s IQOS Platform 1 devices and consumables as Modified Risk
Tobacco Products (MRTPs), finding that exposure modification orders
for these products are appropriate to promote the public health. As
of March 31, 2022, PMI's smoke-free products were available for
sale in 71 markets, and PMI estimates that approximately 12.7
million adults around the world, excluding Russia and Ukraine, had
already switched to IQOS and stopped smoking. With a strong
foundation and significant expertise in life-sciences, in February
2021 PMI announced its ambition to expand into wellness and
healthcare areas and deliver innovative products and solutions that
aim to address unmet consumer and patient needs. For more
information, please visit www.pmi.com and www.pmiscience.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005562/en/
Philip Morris International
Media: Sam Dashiell (202) 480-1617 Email:
Samuel.Dashiell@pmi.com
Philip Morris (NYSE:PM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Philip Morris (NYSE:PM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024